View this email as a webpage

Rutgers Cancer Institute of New Jersey



Clinical Trials Connection

A Cancer Resource for Healthcare Professionals January 2014

Resources for Physicians

Send to a Colleague

Join Our Mailing List

Rajat Bannerji, MD, PhD is a hematologist/ oncologist in the Leukemia/Lymphoma/ Hematologic Malignancies Program at Rutgers Cancer Institute of New Jersey. Dr. Bannerji specializes in the evaluation and treatment of acute and chronic leukemias, lymphomas, myelodysplastic syndromes and myeloproliferative diseases, with a focus on chronic lymphocytic leukemia.

Contact Dr. Bannerji:
bannerra@cinj.rutgers.edu
732-235-7996

New Service Offered

Aiming to promote the early detection of lung

Hematologic Malignancies Clinical Trials

View all related clinical trials View printable version

A Single-arm Study to Assess the Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Intermediate-1, Myelodysplastic Syndrome Patients Based on the International Prognostic Scoring System

The study aims to:

- Determine the onset of hematological improvement according to the 2006 International Working Group (IWG) criteria (see Appendix 1), including RBC transfusion independence, erythroid response, and neutrophil or platelet response, within 24 weeks of starting treatment with oral rigosertib, in transfusion-dependent patients with myelodysplastic syndrome classified as Low or Intermediate-1 in the International Prognostic Scoring System.
- Evaluate rigosertib with respect to overall response (complete and partial responses) according to 2006 IWG criteria (see Appendix 1), including the onset and duration of response and bone marrow response according to 2006 IWG criteria.
- Evaluate the safety of oral rigosertib administered to transfusion-dependent patients with Low or Intermediate-1.

Learn more about this trial

M13-982: A Phase II Open-Label Study of the Efficacy of ABT-199 (GDC-0199) in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia Harboring the 17p Deletion

cancer, Rutgers Cancer Institute of New Jersey has partnered with Robert Wood Johnson University Hospital and University Radiology to offer low cost, low dose CT scans. Individuals who are age 50 or older, a current or former smoker, and have a history of 30 "pack years" of smoking may be eligible for the $99 screening.

Learn more

Other Available Trials

Breast

Gastrointestinal

Gynecologic

Melanoma

Phase I

Prostate

Thoracic

NCI CCC
A Comprehensive Cancer Center Designated by the National Cancer Institute

The study aims to:

- Evaluate the efficacy of ABT-199 monotherapy in subjects with relapsed or refractory chronic lymphocytic leukemia (CLL) harboring the 17p deletion. Efficacy will be measured by overall response rate.
- Evaluate the duration of response, progression-free survival, time to progression, overall survival and percent of subjects who move on to stem cell transplant.
- Evaluate the safety and tolerability of ABT-199 in subjects with relapsed or refractory CLL harboring 17p deletion.

Learn more about this trial

PCI-32765MCL3002: A Randomized, Double-blind, Placebo-controlled Phase III Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Bendamustine and Rituximab (BR) in Subjects with Newly Diagnosed Mantle Cell Lymphoma

The study aims to:

- Evaluate whether the addition of ibrutinib to bendamustine and rituximab will result in prolongation of PFS in subjects with newly diagnosed MCL who are 65 years of age or older.
- Evaluate overall survival, the CR rate and overall response rate (CR+PR).
- Evaluate patient-reported lymphoma symptoms and concerns as measured by the Lym subscale of the Functional Assessment of Cancer Therapy-Lymphoma (FACT-Lym).
- Evaluate the minimal residual disease (MRD) negative rate.
- Evaluate duration of response.

Learn more about this trial

PCI-32765FLR2002: An Open-label, Multicenter, Single-arm, Phase II Study of PCI-32765 (Ibrutinib) in Subjects with Refractory Follicular Lymphoma

The study aims to:

- Evaluate the ORR of PCI-32765, as assessed by the Independent Review Committee, in subjects with chemoimmunotherapy-resistant FL.
- Evaluate the duration of response.
- Evaluate the safety of PCI-32765.
- Evaluate PFS, overall survival and time to response.
- Evaluate incidence of subjects experiencing resolution of lymphoma-related B symptoms.
- Characterize the pharmacokinetics of PCI-32765 after oral dosing.

Learn more about this trial

Phase IA/IB Study of CC-122 for Subjects with Advanced Solid Tumors, NHL and Multiple Myeloma

The study aims to:

- Determine the safety and tolerability of CC-122 given orally and to define the non-tolerable dose, MDT and the recommended Phase II dose.
- Determine the PK and extent of urinary exretion of CC-122.
- Preliminarily assess anti-tumor activity of CC-122.

Learn more about this trial

As New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey offers patients access to treatment options not available at other institutions within the state. The Cancer Institute currently enrolls approximately 17 percent of all new adult cancer patients and approximately 70 percent of all pediatric cancer patients onto a clinical trial. Enrollment in these studies nationwide is fewer than five percent of all adult cancer patients.
Learn more